X-ray Crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition

IUBMB Life

Volumn 62, Issue 6, 2010, Pages 467-476

  Maity, Koustav ^a   Bhargav, Saligram Prabhakar ^a   Sankaran, Banumathi ^b   Surolia, Namita ^c   Surolia, Avadhesha ^a,d   Suguna, Kaza ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b Berkeley Center for Synthetic Biology   (United States)

^c JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Enoyl acyl carrier protein reductase; Halogen groups; Plasmodium falciparum; Triclosan; Triclosan analogs; X ray

Indexed keywords

ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); HALOGEN; TRICLOSAN; WATER;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR INTERACTION; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

ANTI-INFECTIVE AGENTS, LOCAL; CRYSTALLOGRAPHY, X-RAY; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; TRICLOSAN;

PLASMODIUM FALCIPARUM;

EID: 77953581267     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.327     Document Type: Article

References (44)

1. World Health Organization. (2008) WHO World Malaria Report. World Health Organization, Geneva, Switzerland. Available at: http://malaria. who.int/wmr2008/.
2. Mutabingwa, T. K., Anthony, D., Heller, A., Hallett, R., Ahmed, J., Drakeley, C., Greenwood, B. M., and Whitty, C. J. (2005) Amodiaquine alone, amodiaquine1sulfadoxine-pyrimethamine, amodiaquine1artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365, 1474-1480.
3. Surolia, N. and Surolia, A. (2001) Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 7, 167-173.
4. Rock, C. O. and Cronan, J. E. (1996) Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim. Biophys. Acta. 1302, 1-16.
5. Smith, S., Witkowski, A., and Joshi, A. K. (2003) Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 42, 289-317. (Pubitemid 36411688)
6. Ralph, S. A., van Dooren, G. G., Waller, R. F., Crawford, M. J., Fraunholz, M. J., Foth, B. J., Tonkin, C. J., Roos, D. S., and McFadden, G. I. (2004) Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol. 2, 203-216.
7. Surolia, A., Ramya, T. N., Ramya, V., and Surolia, N. (2004) 'FAS't inhibition of malaria. Biochem. J. 383, 401-412.
8. Waller, R. F., Ralph, S. A., Reed, M. B., Su, V., Douglas, J. D., Minnikin, D. E., Cowman, A. F., Besra, G. S., and McFadden, G. I. (2003) A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents. Chemother. 47, 297-301.
9. Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., and Rice, D. W. (1996) A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274, 2107-2110.
10. Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas, A. R., Rice, D. W., and Rafferty, J. B. (1999) Molecular basis of triclosan activity. Nature 398, 383-384.
11. Stewart, M. J., Parikh, S., Xiao, G., Tonge, P. J., and Kisker, C. (1999) Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 290, 859-865.
12. Qiu, X., Janson, C. A., Court, R. I., Smyth, M. G., Payne, D. J., and Abdel-Meguid, S. S. (1999) Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci. 8, 2529-2532.
13. Rozwarski, D. A., Grant, G. A., Barton, D. H., Jacobs, W. R., Jr., and Sacchettini, J. C. (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98-102.
14. Kuo, M. R., Morbidoni, H. R., Alland, D., Sneddon, S. F., Gourlie, B. B., Staveski, M. M., Leonard, M., Gregory, J. S., Janjigian, A. D., Yee, C., Musser, J. M., Kreiswirth, B., Iwamoto, H., Perozzo, R., Jacobs, W. R., Jr., Sacchettini, J. C., and Fidock, D. A. (2003) Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 278, 20851-20859.
15. Lee, H. H., Moon, J., and Suh, S. W. (2007) Crystal structure of the Helicobacter pylori enoyl-acyl carrier protein reductase in complex with hydroxydiphenyl ether compounds, triclosan and diclosan. Proteins 69, 691-694.
16. Muench, S. P., Prigge, S. T., McLeod, R., Rafferty, J. B., Kirisits, M. J., Roberts, C. W., Mui, E. J., and Rice, D. W. (2007) Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr. D Biol. Crystallogr. 63, 328-338.
17. Perozzo, R., Kuo, M., Sidhu, A. S., Valiyaveettil, J. T., Bittman, R., Jacobs, W. R., Jr., Fidock, D. A., and Sacchettini, J. C. (2002) Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem. 277, 13106-13114.
18. Kapoor, M., Dar, M. J., Surolia, A., and Surolia, N. (2001) Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 289, 832-837.
19. Kapoor, M., Reddy, C. C., Krishnasastry, M. V., Surolia, N., and Surolia, A. (2004) Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem. J. 381, 719-724.
20. Kapoor, M., Mukhi, P. L., Surolia, N., Suguna, K., and Surolia, A. (2004) Kinetic and structural analysis of the increased affinity of enoyl- ACP (acyl-carrier protein) reductase for triclosan in the presence of NAD+. Biochem. J. 381, 725-733.
21. Kapoor, M., Gopalakrishnapai, J., Surolia, N., and Surolia, A. (2004) Mutational analysis of the triclosan-binding region of enoyl-ACP (acylcarrier protein) reductase from Plasmodium falciparum. Biochem. J. 381, 735-741.
22. Pidugu, L. S., Kapoor, M., Surolia, N., Surolia, A., and Suguna, K. (2004) Structural basis for the variation in triclosan affinity to enoyl reductases. J. Mol. Biol. 343, 147-155.
23. Chhibber, M., Kumar, G., Parasuraman, P., Ramya, T. N., Surolia, N., and Surolia, A. (2006) Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg. Med. Chem. 14, 8086-8098.
24. Kapoor, N., Banerjee, T., Babu, P., Maity, K., Surolia, N., and Surolia, A. (2009) Design, development, synthesis, and docking analysis of 20-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase. IUBMB Life 61, 1083-1091.
25. Mishra, S., Karmodiya, K., Parasuraman, P., Surolia, A., and Surolia, N. (2008) Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents. Bioorg. Med. Chem. 16, 5536-5546.
26. Kumar, G., Parasuraman, P., Sharma, S. K., Banerjee, T., Karmodiya, K., Surolia, N., and Surolia, A. (2007) Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J. Med. Chem. 50, 2665-2675.
27. Singh, A. P., Surolia, N., and Surolia, A. (2009) Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 61, 923-928.
28. Sivaraman, S., Sullivan, T. J., Johnson, F., Novichenok, P., Cui, G., Simmerling, C., and Tonge, P. J. (2004) Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47, 509-518.
29. Sullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratton, C. F., Li, H. J., Kaur, T., Amin, A., Johnson, F., Slayden, R. A., Kisker, C., and Tonge, P. J. (2006) High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1, 43-53.
30. Freundlich, J. S., Wang, F., Vilcheze, C., Gulten, G., Langley, R., Schiehser, G. A., Jacobus, D. P., Jacobs, W. R., Jr., and Sacchettini, J. C. (2009) Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 4, 241-248.
31. Freundlich, J. S., Yu, M., Lucumi, E., Kuo, M., Tsai, H. C., Valderramos, J. C., Karagyozov, L., Jacobs, W. R., Jr., Schiehser, G. A., Fidock, D. A., Jacobus, D. P., and Sacchettini, J. C. (2006) Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. II. 20-substituted triclosan derivatives. Bioorg. Med. Chem. Lett. 16, 2163-2169.
32. Freundlich, J. S., Anderson, J. W., Sarantakis, D., Shieh, H. M., Yu, M., Valderramos, J. C., Lucumi, E., Kuo, M., Jacobs, W. R., Jr., Fidock, D. A., Schiehser, G. A., Jacobus, D. P., and Sacchettini, J. C. (2005) Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. I. 40-substituted triclosan derivatives. Bioorg. Med. Chem. Lett. 15, 5247-5252.
33. Freundlich, J. S., Wang, F., Tsai, H. C., Kuo, M., Shieh, H. M., Anderson, J. W., Nkrumah, L. J., Valderramos, J. C., Yu, M., Kumar, T. R., Valderramos, S. G., Jacobs, W. R., Jr., Schiehser, G. A., Jacobus, D. P., Fidock, D. A., and Sacchettini, J. C. (2007) X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J. Biol. Chem. 282, 25436-25444.
34. Leslie, A. G. W. (1992) Joint CCP4 + ESF EAMCB Newsletter on Protein Crystallography. No.26.
35. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326.
36. Collaborative Computational Project Number 4. (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763.
37. Storoni, L. C., McCoy, A. J., and Read, R. J. (2004) Likelihoodenhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432-438.
38. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255.
39. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132.
40. Laskowski, R. A., McArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 26, 283-291.
41. Cohen, G. H. (1997) ALIGN: a program to superimpose protein coordinates accounting for insertions and deletions. J Appl Crystallogr. 30, 1160-1161.
42. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921.
43. Schüttelkopf, A. W. and van Aalten, D. M. (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363.
44. Heath, R. J., Yu, Y. T., Shapiro, M. A., Olson, E., and Rock, C. O. (1998) Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273, 30316-30320.